Casma Therapeutics
CompanyUnited StatesFounded 2018
Casma Therapeutics develops one asset, preclinical (CSM-101 in Gaucher disease). Mostly small molecule acting on autophagy and MCOLN1; based in the United States, founded in 2018.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 0
- Signals
Pipeline
1CNS-penetrant small-molecule TRPML1 agonist
Preclinical, Small molecule, Autophagy, MCOLN1, Gaucher disease, Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Similar companies6